# Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

> **NCT05159778** · PHASE2 · COMPLETED · sponsor: **HiberCell, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Malignant Neoplasm of Breast

## Interventions

- **BIOLOGICAL:** Imprime PGG
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05159778
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-09
- **Primary completion:** 2023-03-22
- **Final completion:** 2023-04-12
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05159778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05159778, "Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05159778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*